Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants
Clinical Pharmacology in Drug Development · 2026-02 · 15 (2)
DOI: 10.1002/cpdd.70040 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 19.02.2026. Verfasst von Jingjing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Biomedical Advanced Research and Development Authority, Pfizer Inc. Aztreonam-avibactam, Pfizer and AbbVie.
Abstract (Originalsprache)
Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs). Aztreonam–avibactam may also address other problematic β‐lactamases, such as extended‐spectrum β‐lactamases and serine carbapenemases, which may be co‐expressed with MBLs and contribute to a multidrug‐resistant phenotype. Based on completion of two Phase 3 trials, aztreonam–avibactam was approved in Europe (2024), the United States and China (2025). This Phase 1 open‐label study assessed the pharmacokinetics, safety, and tolerability of aztreonam–avibactam in healthy Chinese participants after single‐ and multiple‐dose administration (doses equivalent to those evaluated in Phase 3 aztreonam–avibactam trials), with a fixed 3:1 ratio. Pharmacokinetics, safety, and tolerability characteristics of aztreonam and avibactam were consistent with previous knowledge, with no clinically significant differences in exposures between Chinese and non‐Chinese participants. Based on population pharmacokinetic modeling which incorporated data from the aztreonam–avibactam Phase 1–3 trials, predicted aztreonam and avibactam exposures at steady state for Phase 3 participants in China and non‐China (rest‐of‐world) regions were numerically similar. These findings indicate that aztreonam–avibactam is well tolerated in healthy Chinese adults and support the use of the approved dose regimen by EMA for Chinese patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Pfizer (China) Research and Development Co., Ltd, Shanghai, China.
- Pfizer Pharmaceutical Ltd., Development China, Beijing, China.
- Pfizer Research & Development, Pfizer Inc., San Diego, CA, USA.
Förderung
- the Biomedical Advanced Research and Development Authority
- Pfizer Inc. Aztreonam-avibactam
- Pfizer and AbbVie
- Innovative Medicines Initiative COMBACTE-CARE group
Zitieren
APA
Wang, J., He, J., Wu, J., Zhang, J., Ma, Y., Ren, X., Wei, H., Zhang, C., Zhu, H., Raber, S. R., & Cong, S. (2026). Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants. Clinical Pharmacology in Drug Development, 15(2). https://doi.org/10.1002/cpdd.70040
Vancouver
Wang J, He J, Wu J, Zhang J, Ma Y, Ren X, et al. Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants. Clinical Pharmacology in Drug Development. 2026;15(2). doi:10.1002/cpdd.70040
BibTeX
@article{Wang2026,
author = {Wang, Jingjing and He, Jinjie and Wu, Jufang and Zhang, Jing and Ma, Ying and Ren, Xiaoqing and Wei, Hua and Zhang, Chunye and Zhu, Hua and Raber, Susan R and Cong, Shuangchen},
title = {Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {2},
doi = {10.1002/cpdd.70040}
}
EUVIMED